Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2003 1
2009 1
2010 1
2011 1
2013 2
2014 2
2017 2
2018 3
2019 4
2020 2
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
CDK8-Novel Therapeutic Opportunities.
Menzl I, Witalisz-Siepracka A, Sexl V. Menzl I, et al. Pharmaceuticals (Basel). 2019 Jun 19;12(2):92. doi: 10.3390/ph12020092. Pharmaceuticals (Basel). 2019. PMID: 31248103 Free PMC article. Review.
Alcohol and retinoids.
Crabb DW, Pinairs J, Hasanadka R, Fang M, Leo MA, Lieber CS, Tsukamoto H, Motomura K, Miyahara T, Ohata M, Bosron W, Sanghani S, Kedishvili N, Shiraishi H, Yokoyama H, Miyagi M, Ishii H, Bergheim I, Menzl I, Parlesak A, Bode C. Crabb DW, et al. Among authors: menzl i. Alcohol Clin Exp Res. 2001 May;25(5 Suppl ISBRA):207S-217S. doi: 10.1097/00000374-200105051-00034. Alcohol Clin Exp Res. 2001. PMID: 11391073 Review.
NK Cell-Specific CDK8 Deletion Enhances Antitumor Responses.
Witalisz-Siepracka A, Gotthardt D, Prchal-Murphy M, Didara Z, Menzl I, Prinz D, Edlinger L, Putz EM, Sexl V. Witalisz-Siepracka A, et al. Among authors: menzl i. Cancer Immunol Res. 2018 Apr;6(4):458-466. doi: 10.1158/2326-6066.CIR-17-0183. Epub 2018 Jan 31. Cancer Immunol Res. 2018. PMID: 29386186 Free article.
A kinase-independent role for CDK8 in BCR-ABL1+ leukemia.
Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, Edlinger L, Knab VM, Uras IZ, Grundschober E, Bauer K, Roth M, Skucha A, Liu Y, Hatcher JM, Liang Y, Kwiatkowski NP, Fux D, Hoelbl-Kovacic A, Kubicek S, Melo JV, Valent P, Weichhart T, Grebien F, Zuber J, Gray NS, Sexl V. Menzl I, et al. Nat Commun. 2019 Oct 18;10(1):4741. doi: 10.1038/s41467-019-12656-x. Nat Commun. 2019. PMID: 31628323 Free PMC article.
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, Rost S, Smith D, Dennis E, Tang SY, Damadzadeh B, Walker E, Hegde PS, Williams JA, Koeppen H, Boyd Z. Vennapusa B, et al. Among authors: menzl i. Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100. doi: 10.1097/PAI.0000000000000594. Appl Immunohistochem Mol Morphol. 2019. PMID: 29346180 Free PMC article.
Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.
Edlinger L, Berger-Becvar A, Menzl I, Hoermann G, Greiner G, Grundschober E, Bago-Horvath Z, Al-Zoughbi W, Hoefler G, Brostjan C, Gille L, Moriggl R, Spittler A, Sexl V, Hoelbl-Kovacic A. Edlinger L, et al. Among authors: menzl i. Br J Haematol. 2017 Oct;179(2):229-241. doi: 10.1111/bjh.14833. Epub 2017 Jul 14. Br J Haematol. 2017. PMID: 28707321 Free PMC article.
Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization.
Huang RSP, Smith D, Le CH, Liu WW, Ordinario E, Manohar C, Lee M, Rajamani J, Truong H, Li J, Choi C, Li J, Pati A, Bubendorf L, Buettner R, Kerr KM, Lopez-Rios F, Marchetti A, Marondel I, Nicholson AG, Öz AB, Pauwels P, Penault-Llorca F, Rossi G, Thunnissen E, Newell AH, Pate G, Menzl I. Huang RSP, et al. Among authors: menzl i. Arch Pathol Lab Med. 2020 Jun;144(6):735-741. doi: 10.5858/arpa.2019-0085-OA. Epub 2019 Sep 11. Arch Pathol Lab Med. 2020. PMID: 31509456 Free article.
Intracellular MUC1 peptides inhibit cancer progression.
Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, Schroeder JA. Bitler BG, et al. Among authors: menzl i. Clin Cancer Res. 2009 Jan 1;15(1):100-9. doi: 10.1158/1078-0432.CCR-08-1745. Clin Cancer Res. 2009. PMID: 19118037 Free PMC article.
19 results